List View

By /

Clear

Displaying 301 - 325 of 2,995

Novel Approaches for Early Stages-Locally Advanced Esophageal and GE Junction Tumors

Novel Approaches for Early Stages-Locally Advanced Esophageal and GE Junction Tumors

Lung Cancer Immunotherapy

Lung Cancer Immunotherapy

RET, MET, and BRAF Mutant Lung Cancer Tumors

RET, MET, and BRAF Mutant Lung Cancer Tumors

Pancreas and Hepatobiliary Tract

Pancreas and Hepatobiliary Tract

HER-2 Disease - Neo-, Adjuvant,Metastatic Setting

HER-2 Disease - Neo-, Adjuvant,Metastatic Setting

NTRK, Exon 20 insertions, and Potential Novel Pathways in Lung Cancer

NTRK, Exon 20 insertions, and Potential Novel Pathways in Lung Cancer

Chronic Lymphocytic Leukemia - Frontline & Relapsed Disease

Chronic Lymphocytic Leukemia - Frontline & Relapsed Disease

Immunotherapy in Head and Neck Cancer

Immunotherapy in Head and Neck Cancer

Managing Expectations-Goals of Care & Family Support

Managing Expectations-Goals of Care & Family Support

Kidney and Bladder Cancers as Targets for Immunotherapy

Kidney and Bladder Cancers as Targets for Immunotherapy

Handling the Most Common Toxicities fromIO - Endocrinopathies, Pneumonitis, SkinRash-Pruritus, and Adrenal Insufficiency

Handling the Most Common Toxicities fromIO - Endocrinopathies, Pneumonitis, SkinRash-Pruritus, and Adrenal Insufficiency

Predictive and Prognostic BiomarkersUsing Genomic Profile in Adjuvant Breast Cancer

Predictive and Prognostic BiomarkersUsing Genomic Profile in Adjuvant Breast Cancer

Immunotherapy in Gastrointestinal Tumors (CRC, Esophageal, and other)

Immunotherapy in Gastrointestinal Tumors (CRC, Esophageal, and other)

Frontline Therapy in Myeloma - How to Decide the Best Approach

Frontline Therapy in Myeloma - How to Decide the Best Approach

Immunologic Therapy for Melanoma

Immunologic Therapy for Melanoma

Current Status of Biosimilars and Recent Approvals

Current Status of Biosimilars and Recent Approvals

The Role of Immunotherapy in Breast Cancer

The Role of Immunotherapy in Breast Cancer

CDK4-6 and PIK3CA Inhibitors in Breast Cancer Management

CDK4-6 and PIK3CA Inhibitors in Breast Cancer Management

B-Cell Lymphomas including Hodgkin’s Disease

B-Cell Lymphomas including Hodgkin’s Disease

Managing Toxicities from B-RAF and MEKInhibitors

Managing Toxicities from B-RAF and MEKInhibitors

Managing Toxicities from TKI EGFR and ALK Inhibitors

Managing Toxicities from TKI EGFR and ALK Inhibitors

Triple-negative and Hereditary Breast Cancer

Triple-negative and Hereditary Breast Cancer

Small Cell Lung Cancer - 2 New IO Regimens as Standard of Care

Small Cell Lung Cancer - 2 New IO Regimens as Standard of Care

Immunotherapy selection in mRCC

Immunotherapy selection in mRCC

Case Presentation - Lung - Immunotherapy Toxicity Case, How to Manage and Whether toPermanently Stop or Not

Case Presentation - Lung - Immunotherapy Toxicity Case, How to Manage and Whether toPermanently Stop or Not